Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of -1.67 is 272% below its 3-year average of 0.97, near the high end of its 3-year range (-198403.23–27.47).
As of the fiscal period ended Tuesday, June 30, 2026. 132.48% below its 12-month average of 5.15.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): -1.67.
DEBT TO EQUITY RATIO
-1.67
DEBT TO EQUITY RATIO AVG TTM
5.15
DEBT TO EQUITY RATIO AVG 3Y
0.97
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-132.48%
CURRENT VS 3Y AVG
-271.91%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 773 covered companies
CURRENT VS SECTOR MEDIAN
-1620.52%
vs the sector median at left
Market Cap
$8.04M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.01
5Y Avg
0.00
Market Cap
$8.14M
Debt to Equity Ratio
N/A
TTM Avg
16.01
3Y Avg
9.73
5Y Avg
9.73
Market Cap
$7.87M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$8.33M
Debt to Equity Ratio
0.26
TTM Avg
1.08
3Y Avg
0.76
5Y Avg
0.48
Market Cap
$7.75M
Debt to Equity Ratio
0.00
TTM Avg
0.06
3Y Avg
0.06
5Y Avg
0.05
Market Cap
$7.67M
Debt to Equity Ratio
0.07
TTM Avg
0.26
3Y Avg
0.17
5Y Avg
0.14
Market Cap
$7.64M
Debt to Equity Ratio
0.03
TTM Avg
0.02
3Y Avg
0.20
5Y Avg
0.20
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DataMEDS AI, Inc. (MEDS) | $8.05M | -1.67 | 5.15 | 0.97 | N/A |
| GT Biopharma, Inc. (GTBP)vs › | $8.04M | 0.00 | 0.00 | 0.01 | 0.00 |
| HeartSciences Inc. (HSCS)vs › | $8.14M | N/A | 16.01 | 9.73 | 9.73 |
| Traws Pharma, Inc. (TRAW)vs › | $7.92M | N/A | 0.00 | 0.00 | 0.00 |
| Aprea Therapeutics, Inc. (APRE)vs › | $7.87M | 0.00 | 0.00 | 0.00 | 0.00 |
| Healthcare Triangle, Inc. (HCTI)vs › | $8.33M | 0.26 | 1.08 | 0.76 | 0.48 |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.75M | 0.00 | 0.06 | 0.06 | 0.05 |
| ENDRA Life Sciences Inc. (NDRA)vs › | $7.67M | 0.07 | 0.26 | 0.17 | 0.14 |
| Mangoceuticals, Inc. (MGRX)vs › | $7.64M | 0.03 | 0.02 | 0.20 | 0.20 |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.46M | 0.00 | 0.33 | 0.17 | 0.11 |
Debt/Equity
-1.67
Current Ratio
0.14
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | -1.67 |
| 2026-03-31 | -1.92 |
| 2025-12-31 | -1.99 |
| 2025-09-30 | 3.87 |
| 2025-06-30 | 27.47 |
| 2025-03-31 | 5.75 |
| 2024-12-31 | 3.73 |
| 2024-09-30 | 2.21 |
| 2024-06-30 | -24.03 |
| 2024-03-31 | -198403.23 |
| 2023-12-31 | -0.24 |
| 2023-09-30 | 0.00 |
| 2023-06-30 | 0.00 |
